Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: J Orthop Res. 2009 Nov;27(11):1514–1520. doi: 10.1002/jor.20915

Table 1. Demographics.

Group 1 (patent AV bundle, no immunosuppression (IS); group 2 (ligated AV bundle, no IS); group 3 (patent, Tacrolimus IS); group 4 (ligated AV bundle, Tacrolimus IS).

Group AV-Bundle Immunosuppression n N left for relative expression ratio measurement*
1 Patent None 11 10
2 Ligated None 7 4
3 Patent TACROLIMUS, 2 weeks 11 10
4 Ligated TACROLIMUS, 2 weeks 9 7
*

Specimens with enough tissue left for DNA extraction.